View Post

LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Gina Columbus From: onclive.come The oral selective estrogen receptor degrader (SERD) LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib (Kisqali) or alpelisib (Piqray) in patients with estrogen receptor (ER)–positive breast cancer who have progressed on endocrine therapy, according to findings of a phase 1/1b trial that were presented during the 2020 …